Aprea Strengthens its Board
Aprea AB has announced that Bernd R. Seizinger has been elected as a new member of the board. Bernd R. Seizinger, M.D., Ph.D., is Chairman of Opsona Therapeutics Ltd. and former Vice President, Oncology Drug Discovery at Bristol-Myers Squibb, Associate Professor of Neuroscience at Harvard Medical School and Associate Geneticist and Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital in Boston, MA, USA.
“We are pleased to welcome Dr. Seizinger to the board”, says Torbjörn Bjerke, Chairman of Aprea AB. “His extensive research and clinical development experience within oncology from the pharmaceutical and biotechnology industries will be a great benefit to the company as we move forward.”
As biotech and pharma senior executive, Dr. Seizinger has held a number of positions such as President & CEO of oncology drug discovery and clinical development company GPC Biotech (Munich, Boston, Princeton, Houston), Vice-President Oncology Drug Discovery at Bristol-Myers Squibb (Princeton), Executive Vice President and Chief Scientific Officer at Genome Therapeutics (Boston), as well as Executive Chairman/Interim CEO at Opsona Ltd. (Dublin).
In addition to his current Board memberships at Opsona Ltd., Agennix AG, and TriMod Ltd., Dr. Seizinger previously held Board memberships at Altana Pharma AG, Santhera Pharmaceuticals, BioXell Spa, and Cytovia Inc.
Dr. Seizinger has authored more than 100 publications and has been the recipient of numerous scientific awards, including the Otto-Hahn-Medal of the Max-Planck-Society, the Wilson S. Stone Award for Cancer Research (U.S), and the von Recklinghausen Award by the U.S. National Neurofibromatosis Foundation.